Tesamorelin ���景与作用机制 — Questions and Answers

By Editorial Desk · published 2025-11-28 · last reviewed 2025-12-18 · Data

The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

Background and Pharmacology of Tesamorelin

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.

Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.

Tesamorelin at a glance

Tesamorelin Background and Mechanism

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Related pages on this site

• Connected reference
• Reliable overview
• Professional report
• Adaptive comparison
• Standard archive
• Tracked notes
• Measured update
• Clear guide

Background and Receptor Mechanism

Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.

Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Supporting material

=== Official === President Joe Biden official website (archived) Presidential campaign website at the Wayback Machine (archived July 18, 2024) Obama White House biography (archived) Senator Joseph R. Biden (1973–2009)

The authors speculated that the difference may be because the people that discontinued treatment after a longer time had more severe mental illness than those that discontinued antipsychotic therapy sooner. A significant challenge in the use of antipsychotic drugs for the prevention of relapse is the poor rate of adherence. In spite of the relatively high rates of adverse effects associated with these drugs, some evidence, including higher dropout rates in placebo arms compared to treatment arms in randomized clinical trials, suggests that most patients who discontinue treatment do so because of suboptimal efficacy. If someone experiences psychotic symptoms due to nonadherence, they may be compelled to receive treatment through a process called involuntary commitment, in which they can be forced to accept treatment (including antipsychotics). A person can also be committed to treatment outside of a hospital, called outpatient commitment. Antipsychotics in long-acting injectable (LAI), or "depot", form have been suggested as a method of decreasing medication nonadherence (sometimes also called non-compliance). NICE advises LAIs be offered to patients when preventing covert, intentional nonadherence is a clinical priority. LAIs are used to ensure adherence in outpatient commitment. A meta-analysis found that LAIs resulted in lower rates of rehospitalization with a hazard ratio of 0.83; however, these results were not statistically significant (the 95% confidence interval was 0.62 to 1.11).

== Function == The broad distribution of relaxin-3 fibres/RXFP3 within several key neuronal circuits suggests an ability to modulate a broad range of behaviours. This has been confirmed in a growing number of rodent studies, which demonstrate relaxin-3 is able to modulate arousal, the response to stress, feeding/metabolism and memory; and likely plays a role in the generation/regulation of hippocampal theta rhythm.

== Economy == Major employers in Lebanon include Lebanon Community School Corporation; the U.S. headquarters of German power tools company Festool and of Canadian specialty foods manufacturer Skjodt-Barrett; manufacturing plants for Hendrickson International, DS Smith, Kuraray, Kauffman Engineering, Maplehurst Bakeries, and D-A Lubricant Company; distribution centers for CNH Parts & Services, Subaru of America, Continental Tire the Americas, and Hachette Book Group USA; and health care and medical facilities operated by Witham Health Services. Lebanon is also the site of LEAP Research and Innovation District, an economic development initiative involving over 9,000 acres of land that will be allocated for technological and manufacturing projects. The area will be able to employ around 50,000 workers upon completion. Among the investments at LEAP is a $9 billion facility for Eli Lilly and Company that will produce active pharmaceutical ingredients for the antidiabetic medication Tirzepatide starting in late 2026.

The development of MPAA ligands enabled and improved the synthesis of many complex natural products. Examples include Arnottin 1, Aspercylide B, Berkelic Acid, Boletopsin 11, Danshenspiroketallactone, Delavatine A, Herbindole B/cis-Trikentrin A, Hongoquercin A, Incarviatone A, Indoxamycin, Kedarcidin/Neocarzinostatin, Kinamycin , Lithospermic Acid, M1 PAMs, and VS-548. In the formation of indoxamycin cores, MPAA ligand assisted C–H functionalization introduces high complexity via intramolecular ortho olefination.

Sources: en.wikipedia.org

Supporting material

Her two manuscripts on form A DNA reached Acta Crystallographica in Copenhagen on 6 March 1953, one day before Crick and Watson had completed their model. The X-ray diffraction images collected by Gosling and Franklin provided the best evidence for the helical nature of DNA. Before this, both Linus Pauling, Watson, and Crick had generated erroneous models with the chains inside and the bases pointing outwards. Her experimental results provided estimates of the water content of DNA crystals, and these results were most consistent with the three sugar-phosphate backbones being on the outside of the molecule. Franklin's X-Ray photograph showed that the backbones had to be on the outside. Although she at first insisted vehemently that her data did not force one to conclude that DNA has a helical structure, in the drafts she submitted in 1953 she argues for a double helical DNA backbone. Building on her manuscripts, she discovered that form A DNA had antiparallel backbones, which supported the double helical structure of DNA. She did this through identification of the space group for DNA crystals. This would go to help Watson and Crick decide to look for DNA models with two antiparallel polynucleotide strands. In summary, Watson and Crick had three sources for Franklin's unpublished data: 1) her 1951 seminar, attended by Watson, 2) discussions with Wilkins, who worked in the same laboratory with Franklin, 3) a research progress report that was intended to promote coordination of Medical Research Council–supported laboratories.

The developers said they had to drop some features from the mod due to limitations of the Half-Life engine. PC Zone gave a rating of 71% for the LAN-only version and a rating of 72% for the online-compatible version, saying the online component is "very weak" and LAN is still the preferred way to play. PC Action called it a challenging and fun mod. Lambda Arena – A version of the Quake series mod Rocket Arena, released in 1999. It is mainly for one versus one matches but the mod supports teamplay up to four players. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "Lambda Arena has a great American Gladiators feel, with gaudy but functional arenas." Master Sword – A cooperative fantasy role-playing total conversion mod. During character creation, the player has the option to select a race, which can be either human, dwarf, or elf. The available classes include wizard, archer, and rogue. Incite PC Games gave the mod a score of seven out of ten. The mod received an expansion titled Master Sword: Continued. PC Action gave the expansion a "good" rating. Natural Selection – A mod in which two teams (humans and aliens) fight against each other. Its utilizes a mixture of first-person shooter and real-time strategy gameplay. It gained a standalone successor, Natural Selection 2. The Opera – Released on July 9, 2001. The gameplay features diving, rolling, and dual wielding that is described as "gun ballet". The game features minimal heads-up display (HUD) with no ammo, health or armour displayed. The mod was in production for two years.

There is high interindividual variability in the levels of estradiol achieved with oral estradiol, which is likely related to the high first-pass effect. This variation has been reported to be in the range of 28 to 127%, or about 4.6-fold maximal difference in levels between individuals, in terms of mean area-under-the-curve levels of estradiol. In postmenopausal women, a dosage of 1 mg/day oral micronized estradiol has been found to produce circulating concentrations of 30 to 50 pg/mL estradiol and 150 to 300 pg/mL estrone, while a dosage of 2 mg/day has been found to result in circulating levels of 50 to 180 pg/mL estradiol and 300 to 850 pg/mL estrone. A study of oral micronized estradiol in transgender women found that mean estradiol levels across a dosage range of 1 to 8 mg/day were about 50 pg/mL at 1 mg/day, 100 pg/mL at 4 mg/day, and 150 pg/mL at 8 mg/day, with a wide degree of variation. In another study, mean estradiol levels at steady state with 4 mg/day and 6 mg/day oral micronized estradiol were approximately 180 pg/mL and 265 pg/mL, respectively. A study that used high to very high-dose oral micronized estradiol in postmenopausal women found that steady-state estradiol levels with 6 mg/day were about 300 pg/mL and with 30 mg/day were about 2,400 pg/mL. Estradiol valerate is rapidly hydrolyzed into estradiol in the intestines. For this reason, oral estradiol and oral estradiol valerate have very similar pharmacokinetics.

Both pathways rely on 5α-reductase, but in the androgen backdoor pathway, this enzyme acts on C21 steroids (pregnanes), initiating a series of chemical reactions that eventually lead to dihydrotestosterone production. In contrast, in the canonical pathway, 5α-reductase targets the 4,5-double bond in testosterone, producing dihydrotestosterone directly. The backdoor pathway was initially described as a biosynthetic route where 5α-reduction of 17α-hydroxyprogesterone ultimately leads to dihydrotestosterone. Since then, several other pathways have been discovered that lead to 11-oxygenated androgens which are also physiologically significant.

Sources: en.wikipedia.org

Frequently asked questions